ArticleBreast cancer research and treatment2016

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.

Christopher M Gallagher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.